Peter Altman
Director Ejecutivo en BIOCARDIA INC .
Fortuna: 205 600 $ al 30/04/2024
Cargos activos de Peter Altman
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| BIOCARDIA INC | Director/Miembro de la Junta | 01/01/2002 | - |
| Director Ejecutivo | 01/01/2002 | - | |
| Presidente | 01/01/2002 | - | |
| Oncocyclist Biotech | Director/Miembro de la Junta | 01/01/2018 | - |
BioCardia Lifesciences, Inc.
 BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Director Ejecutivo | - | - |
Historial de carrera de Peter Altman
Antiguos cargos conocidos de Peter Altman.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CAREDX, INC | Director/Miembro de la Junta | 01/01/1999 | 01/01/2014 |
| Director Ejecutivo | 01/01/1999 | 01/01/2003 | |
| Fundador | 01/01/1998 | 01/01/2014 | |
Lumen Therapeutics
 Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Director Ejecutivo | 01/01/2004 | 01/01/2005 |
| Fundador | 01/01/2004 | 01/01/2005 | |
BioCardia, Inc. /Old/
 BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Director/Miembro de la Junta | 01/01/2002 | - |
| Director Ejecutivo | 01/01/2002 | - | |
| Presidente | 01/01/2002 | - | |
Ventritex, Inc.
 Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Corporate Officer/Principal | - | - |
Sinus Rhythm Technologies, Inc.
 Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Corporate Officer/Principal | - | - |
Formación de Peter Altman.
| University of California, Berkeley | Doctorate Degree |
| The University of California, San Francisco | Doctorate Degree |
| Fu Foundation School of Engineering & Applied Science | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 12 |
Operativa
| Chief Executive Officer | 5 |
| Director/Board Member | 4 |
| Founder | 2 |
Sectorial
| Health Technology | 8 |
| Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| CAREDX, INC | Health Technology |
| BIOCARDIA INC | Health Technology |
| Empresas privadas | 6 |
|---|---|
Ventritex, Inc.
Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Health Technology |
Sinus Rhythm Technologies, Inc.
Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Health Technology |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
Lumen Therapeutics
Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Health Technology |
BioCardia Lifesciences, Inc.
BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Health Technology |
| Oncocyclist Biotech |
- Bolsa de valores
- Insiders
- Peter Altman
- Experiencia
